A detailed history of Engineers Gate Manager LP transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Engineers Gate Manager LP holds 18,390 shares of ESPR stock, worth $42,297. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,390
Holding current value
$42,297
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.61 - $2.73 $29,607 - $50,204
18,390 New
18,390 $30,000
Q4 2023

Feb 14, 2024

BUY
$0.73 - $3.08 $3,314 - $13,986
4,541 Added 9.38%
52,932 $158,000
Q3 2023

Nov 14, 2023

SELL
$0.96 - $1.79 $23,423 - $43,674
-24,399 Reduced 33.52%
48,391 $47,000
Q2 2023

Aug 14, 2023

BUY
$1.2 - $1.76 $87,348 - $128,110
72,790 New
72,790 $101,000
Q3 2022

Nov 14, 2022

BUY
$5.45 - $8.13 $79,548 - $118,665
14,596 New
14,596 $98,000
Q1 2022

May 16, 2022

SELL
$3.34 - $5.56 $42,094 - $70,072
-12,603 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$4.81 - $11.92 $232,438 - $576,022
-48,324 Reduced 79.31%
12,603 $63,000
Q3 2021

Nov 15, 2021

BUY
$11.34 - $21.37 $262,532 - $494,736
23,151 Added 61.28%
60,927 $734,000
Q2 2021

Aug 16, 2021

BUY
$19.4 - $28.71 $94,361 - $139,645
4,864 Added 14.78%
37,776 $799,000
Q1 2021

May 17, 2021

BUY
$25.12 - $36.89 $4,998 - $7,341
199 Added 0.61%
32,912 $923,000
Q4 2020

Feb 16, 2021

BUY
$24.2 - $35.76 $791,654 - $1.17 Million
32,713 New
32,713 $851,000
Q3 2020

Nov 16, 2020

SELL
$31.18 - $52.71 $275,007 - $464,902
-8,820 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$30.04 - $51.31 $264,952 - $452,554
8,820 New
8,820 $453,000
Q3 2019

Nov 14, 2019

SELL
$34.47 - $47.53 $289,513 - $399,204
-8,399 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$40.1 - $52.33 $336,799 - $439,519
8,399 New
8,399 $391,000

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $153M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.